Induction of apoptosis in cancer cells

Description:
Adamantyl-substituted retinoid related molecules are a unique class of compounds which have been found to induce apoptosis, or cell death, in many different tumor types. Currently, there is an unmet medical need for cancer treatments that display enhanced pharmacologic properties such as bioavailability, increased solubility or less toxicity, particularly for cancers such as leukemias. The current invention provides apoptosis inducing compounds for the treatment of various cancer types, including leukemias.
 
The present invention provides compounds that are useful inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. This invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
 
 U.S. Patent: 7,053,071
 
-02-35
 
 
 
Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Jianbo Hu
IP & Licensing Manager
Oregon State University
Jianbo.Hu@oregonstate.edu
Inventors:
Mark Leid
Marcia Dawson
Joseph Fontanta
Xiao-kun Zhang
Ling Jong
Peter Hobbs
Keywords:
Biomedical
Biotechnology
Medical Science & Technologies
Pharmaceuticals
© 2014. All Rights Reserved. Powered by Inteum